Prosecution Insights
Last updated: May 29, 2026

Flagship Pioneering Innovations V Inc.

11 pending office actions • 8 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

11
Total Pending OAs
6
Non-Final OAs
5
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

8
Overdue
1
Due this week
0
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (8)Due ≤ 7 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
7
Medium (64%)
1
Easy (9%)
3
Unknown (27%)

Rejection Statute Mix

BucketCases
§103 only6 (55%)
§102 only1 (9%)
§112 only1 (9%)
No statute on record3 (27%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

11
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

110 h
Manual time on pending OAs
22 h
Time saved (low, 20%)
38 h
Time saved (mid, 35%)
1.0 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LEITH, NANCY J 2 74.7% +43.8%
WANG, RUIXUE 1 57.6% +23.2%
LIU, TRACY 1 54.9% +28.0%
BERKE-SCHLESSEL, DAVID W 1 66.5% +32.1%
KELLY, ROBERT M 1 74.1% +24.6%
THUESON, HANNA MARIE 1 71.4% +30.8%
DACE DENITO, ALEXANDRA GERALDINE 1 56.5% +36.3%
SMALL, KATHERINE R 1 65.4% +29.7%
MIANO, JOSEPH PAUL 1 37.9% +63.3%
RIGA, MICHAEL ANGELO 1 51.8% +63.5%

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18009476 BACULOVIRUS EXPRESSION SYSTEMS THUESON, HANNA MARIE 114d overdue
18009557 TANDEM ANELLOVIRUS CONSTRUCTS LEITH, NANCY J 81d overdue
18250621 CHICKEN ANEMIA VIRUS (CAV)-BASED VECTORS WANG, RUIXUE 73d overdue
17413297 ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES DACE DENITO, ALEXANDRA GERALDINE 45d overdue
18004403 METHODS AND COMPOSITIONS FOR PRODUCING VIRAL FUSOSOMES BERKE-SCHLESSEL, DAVID W 42d overdue
16970216 COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY RIGA, MICHAEL ANGELO 28d overdue
17055077 FUSOSOME COMPOSITIONS AND USES THEREOF MIANO, JOSEPH PAUL 15d overdue
17293802 FUSOSOME COMPOSITIONS FOR T CELL DELIVERY LEITH, NANCY J 11d overdue

Top Art Units

Art UnitApps
1636 3
1638 2
1672 1
1614 1
1651 1
1633 1
1631 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18250621 CHICKEN ANEMIA VIRUS (CAV)-BASED VECTORS WANG, RUIXUE 1672 §103 Non-Final OA 73d overdue Pending Apr 26, 2023
18154618 COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF LIU, TRACY 1614 §103 Final Rejection 5d Pending Jan 13, 2023
18004403 METHODS AND COMPOSITIONS FOR PRODUCING VIRAL FUSOSOMES BERKE-SCHLESSEL, DAVID W 1651 Other Final Rejection 42d overdue Pending Jan 05, 2023
18010674 METHODS OF IDENTIFYING AND CHARACTERIZING ANELLOVIRUSES AND USES THEREOF KELLY, ROBERT M 1638 §112 Non-Final OA 69d Pending Dec 15, 2022
18009476 BACULOVIRUS EXPRESSION SYSTEMS THUESON, HANNA MARIE 1638 §102 Non-Final OA 114d overdue Pending Dec 09, 2022
18009557 TANDEM ANELLOVIRUS CONSTRUCTS LEITH, NANCY J 1636 §103 Final Rejection 81d overdue Pending Dec 09, 2022
17413297 ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES DACE DENITO, ALEXANDRA GERALDINE 1636 Other Non-Final OA 45d overdue Pending Jun 11, 2021
17293802 FUSOSOME COMPOSITIONS FOR T CELL DELIVERY LEITH, NANCY J 1636 §103 Final Rejection 11d overdue Pending May 13, 2021
17293797 FUSOSOME COMPOSITIONS FOR HEMATOPOIETIC STEM CELL DELIVERY SMALL, KATHERINE R 1633 §103 Final Rejection 57d Pending May 13, 2021
17055077 FUSOSOME COMPOSITIONS AND USES THEREOF MIANO, JOSEPH PAUL 1631 Other Non-Final OA 15d overdue Pending Nov 12, 2020
16970216 COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY RIGA, MICHAEL ANGELO 1634 §103 Non-Final OA 28d overdue Pending Aug 14, 2020

Managing Flagship Pioneering Innovations V Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month